Alcohol Use Disorder, Hepatitis C
Conditions
Keywords
Hepatitis C, Direct-acting antiviral therapies, DAA, Chronic HCV infection, Alcohol Use Disorder
Brief summary
The primary objective of this research project is to compare neuropsychiatric functioning, cortical activity, white matter integrity, and immune response among Veterans with and without alcohol use disorder (AUD), before and after direct-acting antiviral (DAA) therapy \[a new treatment for chronic infection with the hepatitis C virus (HCV)\]. Demographically-matched comparison groups of Veterans without HCV (HCV-, with and without AUD) will similarly be evaluated to determine the relative contribution of HCV and an HCV cure to outcomes putatively affected by alcohol abuse. Two specific aims are proposed. Aim 1: Determine the impact of DAA therapy and a sustained viral response on central nervous system (CNS) function. Aim 2: Evaluate the effects of AUD and unhealthy alcohol drinking on DAA therapy outcomes and CNS function. The information learned will address a critical gap in knowledge concerning the effects of alcohol use on DAA therapy outcomes and will help inform treatment guidelines that could be translated to clinical practice, such as targeted interventions to treat AUD in conjunction with HCV infection and follow-up strategies for patients who successfully complete DAA therapy but then need care for other potential CNS-related outcomes.
Detailed description
Aim 1 will evaluate the impact of DAA therapy on CNS function in Veterans with HCV and will test the hypotheses that following DAA therapy and obtaining a sustained viral response (SVR) \[i.e., when the virus continues to be undetectable in blood 12 weeks (or more) after completing therapy\], participants will show: i) improved neuropsychiatric outcomes (e.g., cognitive function, fatigue, mood), as compared to baseline (pre-DAA therapy), ii) restored functional connectivity and structural integrity within white matter tracks that had been observed at baseline, and iii) reduced immune activation profiles (e.g., decreased expression of inflammatory biomarkers and restored T cell balance), as compared to baseline. Aim 2 will determine the impact of an active AUD on the neuropsychiatric, neuroimaging, and immunological outcomes observed in aim 1. Participants will be evaluated at two time points \[i.e., baseline and 12 weeks post-therapy (week 24)\]. Evaluations will incorporate brain imaging methods \[i.e., resting state magnetic resonance imaging (MRI), functional MRI, and diffusion tensor imaging\] along with clinical and laboratory methods to assess the interactive effects of alcohol use and HCV on brain function. Clinical and laboratory data will include: i) demographic and medical information, ii) neuropsychological measures of attention, memory, and executive function, iii) neuropsychiatric symptom questionnaires (e.g., depression and anxiety), iv) urine and oral fluid collection for medical laboratory tests, and v) blood sample collection for planned experiments (e.g., flow cytometry, quantitative polymerase chain reaction (qPCR), and multiplex immunoassays) and for contribution to the VA Liver Disease Repository. Evidence-based guidelines for the new DAA therapies are needed (e.g., How much alcohol is too much?). The VA is at the forefront of treating HCV and is now offering DAA therapy to all Veterans with HCV treated within VA health care systems. The proposed studies will address a critical gap in our knowledge concerning the effects of co-morbid HCV and AUD on antiviral therapy outcomes, particularly CNS function and neuropsychiatric symptoms that contribute to addiction and relapse.
Interventions
Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
Subjects, well characterized with respect to their substance use, will be evaluated with functional magnetic resonance imaging (fMRI) tasks, resting state MRI (rsMRI), high resolution anatomical MRI, standard diffusion weighted imaging (DWI) and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult Veteran (\>21 years) * Able to provide informed consent.
Exclusion criteria
* Current substance use disorder other than alcohol (except nicotine or caffeine) * Medical conditions likely to impact immunological function or central nervous system function (such as HIV, cancer, lupus, stroke, neurodegenerative disease, hepatic encephalopathy, multiple sclerosis, or a traumatic brain injury) * Visible intoxication or impaired capacity to understand study risks and benefits or otherwise provide informed consent * Past or present schizophrenia, schizoaffective disorder, or current psychosis or mania * Visual or auditory impairments that would prevent valid neuropsychiatric testing * Contraindications to MRI (such as surgical aneurysm clips, pacemaker, prosthetic heart valve, neuro-stimulator, implanted pumps, cochlear implants, metal rods, plates or screws, previous surgery, hearing aids, history of welding, metal shrapnel)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores | Baseline and 6 months | The Attention Module is a marker of attentional capacity, working memory, and processing speed. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Attention Module subtests include: Dots, Numbers and Letters, Driving Scenes, Digits Forward, and Digits Backward. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in attention performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of attention performance over time. |
| Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores | Baseline and 6 months | The Memory Module is a marker of learning, recall, and recognition memory. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Memory Module subtests include: List Learning, Shape Learning, Story Learning, and Daily Living Memory. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in memory performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of memory performance over time. |
| Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores | Baseline and 6 months | The Executive Functions Module of the NAB is a marker of executive function, including problem-solving and mental flexibility. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Executive Function Module subtests include: Mazes, Judgement, Categories, and Word Generation. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in executive function performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of executive functioning performance over time. |
| Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB) | Baseline and 6 months | This outcome measure evaluates the change in the number of days of alcohol use from baseline to a 6-month follow-up, using the 30-Day Timeline Followback (TLFB) method. The TLFB is a structured, retrospective interview technique that allows participants to accurately recall their alcohol consumption patterns over the previous 30 days. For this outcome, the number of days on which alcohol was consumed will be assessed at baseline (the start of the study) and again at the 6-month follow-up assessment. A positive change would indicate an increase in the number of days of alcohol use, while a negative change would indicate a reduction in the number of days of alcohol use over the 6-month period. |
| Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART) | Baseline and 6 months | The BART is a computerized measure of risk-taking behavior that concurrently measures several domains (i.e., risky decision-making, reward/negative outcome processing) during fMRI scanning. The ratio of balloon pumps made to maximum pumps allowed is a measure of risk-taking behavior. A ratio of 1 indicates that a participant inflated the balloon to its maximum allowed pumps, while a ratio closer to 0 suggests that the participant was much more conservative in their approach. Change was calculated as the value at 6 months minus the value at baseline and ranges from -1 to 1. A positive change indicates an increase in risk-taking behavior and a negative change indicates a decrease in risk-taking behavior over time. |
| Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task | Baseline and 6 months | The MID is a validated task to examine anticipatory brain responses to reward during fMRI scanning. This outcome measure evaluates the change in reaction time (RT) of participants in response to monetary reward cues during the MID. Reaction time is defined as the duration (in milliseconds) from the presentation of the cue to the participant's response (e.g., button press). The MID involves various reward conditions, including different monetary values and probabilities, allowing for an evaluation of participants' anticipatory responses to potential rewards. A positive difference indicates an increase in RT at 6-months compared to baseline, suggesting potential decreases in motivation, cognitive load, or changes in reward sensitivity. Conversely, a negative difference indicates a decrease in reaction time, which may reflect improved motivation, enhanced cognitive processing speed, or increased responsiveness to monetary incentives over time. |
| Change in Fatigue Severity Scale (FSS) Score | Baseline and 6 months | The Fatigue Severity Scale (FSS) is a 9-item self-report questionnaire designed to measure level of fatigue. The FSS is graded on a 7-point Likert-like scale ranging from 1 (strongly disagree) to 7 (strongly agree). The score for all 9 items is summed to constitute the FSS score. The minimum FSS score is 7 and the maximum score possible is 63. A higher score represents greater fatigue severity. Change was calculated as the value at 6 months minus the value at baseline and reported here. A higher positive score indicates an increase in fatigue symptoms at 6 months compared to baseline, a lower negative score would indicate a decrease in fatigue symptoms over 6 months and a score of 0 would indicate no change in fatigue symptoms over 6 months. |
| Change in Beck Depression Inventory Second Edition (BDI-II) Score | Baseline and 6 months | The Beck Depression Inventory Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory that measures depression. There is a four-point scale for each item ranging from 0-3. The total score can range from 0 to 63 points. Higher scores reflect a great level of depression severity. |
| Change in Fractional Anisotropy (FA) in White Matter Tracts | Baseline and 6 months | MRI-based diffusion tensor imaging (DTI) tractography is used to measure fractional anisotropy (FA), an indicator of CNS microstructural integrity. Increases in FA may reflect enhanced fiber organization or myelination, while decreases often indicate demyelination, axonal loss, or reduced coherence of white matter tracts. The JHU white-matter tractography atlas was used to extract FA values from 20 structures. Percent change was calculated. A positive number indicates an increase in FA after 6 months and a negative number indicates a decrease in FA from baseline to 6 months. |
| Change in Mean Diffusivity (MD) in White Matter Tracts | Baseline and 6 months | MRI-based diffusion tensor imaging (DTI) tractography is used to measure mean diffusivity (MD), which is the average rate of water diffusion in all directions within brain tissue. An increase in MD often indicates microstructural disruption, such as axonal loss, demyelination, or increased extracellular space due to edema or atrophy and decreases in MD can reflect cellular proliferation or restricted diffusion, as seen in certain types of gliosis or inflammatory conditions. The JHU white-matter tractography atlas was used to extract MD values from 20 structures. Percent change was calculated. A positive number indicates an increase in MD after 6 months and a negative number indicates a decrease in MD from baseline to 6 months. |
| Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | Baseline and 6 months | Change was calculated as the value at 6 months minus the value and baseline. A positive number indicates an increase in inflammatory markers in plasma samples and a negative value indicates a decrease in inflammatory markers at 6 months. |
Countries
United States
Participant flow
Pre-assignment details
Of 119 assessed for eligibility, 63 met inclusion criteria (38 AUD-/HCV-, 20 AUD+/HCV-, 5 HCVc) and were enrolled in the study. 17 participants were excluded after enrollment. Due to low recruitment numbers and no significant differences between the HCV groups, individuals with a history of HCV were assigned to one group (HCVc).
Participants by arm
| Arm | Count |
|---|---|
| Control (AUD-) -Without Alcohol Use Disorder and without HCV
Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later. | 27 |
| Alcohol Use Disorder (AUD+) -With Alcohol Use Disorder and without HCV
Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later. | 14 |
| HCVc -Adults treated for HCV
Neuropsychological assessment: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
Neuroimaging: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later. | 5 |
| Total | 46 |
Baseline characteristics
| Characteristic | Control (AUD-) | Total | HCVc | Alcohol Use Disorder (AUD+) |
|---|---|---|---|---|
| Age, Continuous | 53.70 years STANDARD_DEVIATION 14.87 | 56.59 years STANDARD_DEVIATION 14.1 | 63.40 years STANDARD_DEVIATION 5.37 | 59.71 years STANDARD_DEVIATION 13.84 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 3 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants | 43 Participants | 5 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 3 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 8 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 3 Participants | 3 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 16 Participants | 31 Participants | 3 Participants | 12 Participants |
| Region of Enrollment United States | 27 Participants | 46 Participants | 5 Participants | 14 Participants |
| Sex: Female, Male Female | 9 Participants | 14 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Male | 18 Participants | 32 Participants | 4 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 27 | 0 / 14 | 0 / 5 |
| other Total, other adverse events | 0 / 27 | 0 / 14 | 0 / 5 |
| serious Total, serious adverse events | 0 / 27 | 0 / 14 | 0 / 5 |
Outcome results
Change in Beck Depression Inventory Second Edition (BDI-II) Score
The Beck Depression Inventory Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory that measures depression. There is a four-point scale for each item ranging from 0-3. The total score can range from 0 to 63 points. Higher scores reflect a great level of depression severity.
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Change in Beck Depression Inventory Second Edition (BDI-II) Score | 2.48 score on a scale | Standard Deviation 5.98 |
| Alcohol Use Disorder (AUD+) | Change in Beck Depression Inventory Second Edition (BDI-II) Score | 1.92 score on a scale | Standard Deviation 7.39 |
| HCVc | Change in Beck Depression Inventory Second Edition (BDI-II) Score | -0.60 score on a scale | Standard Deviation 4.83 |
Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART)
The BART is a computerized measure of risk-taking behavior that concurrently measures several domains (i.e., risky decision-making, reward/negative outcome processing) during fMRI scanning. The ratio of balloon pumps made to maximum pumps allowed is a measure of risk-taking behavior. A ratio of 1 indicates that a participant inflated the balloon to its maximum allowed pumps, while a ratio closer to 0 suggests that the participant was much more conservative in their approach. Change was calculated as the value at 6 months minus the value at baseline and ranges from -1 to 1. A positive change indicates an increase in risk-taking behavior and a negative change indicates a decrease in risk-taking behavior over time.
Time frame: Baseline and 6 months
Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, one control participant and one participant with cleared HCV (HCVc) were not included in the analysis because task data from at least one timepoint was not collected.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART) | -0.018 ratio | Standard Deviation 0.093 |
| Alcohol Use Disorder (AUD+) | Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART) | -0.005 ratio | Standard Deviation 0.079 |
| HCVc | Change in Behavior as Assessed by the Balloon Analogue Risk Task (BART) | -0.014 ratio | Standard Deviation 0.164 |
Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task
The MID is a validated task to examine anticipatory brain responses to reward during fMRI scanning. This outcome measure evaluates the change in reaction time (RT) of participants in response to monetary reward cues during the MID. Reaction time is defined as the duration (in milliseconds) from the presentation of the cue to the participant's response (e.g., button press). The MID involves various reward conditions, including different monetary values and probabilities, allowing for an evaluation of participants' anticipatory responses to potential rewards. A positive difference indicates an increase in RT at 6-months compared to baseline, suggesting potential decreases in motivation, cognitive load, or changes in reward sensitivity. Conversely, a negative difference indicates a decrease in reaction time, which may reflect improved motivation, enhanced cognitive processing speed, or increased responsiveness to monetary incentives over time.
Time frame: Baseline and 6 months
Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, two participants (1 HCVc, 1 AUD) were excluded from the study for having incomplete task data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task | -0.39 milliseconds | Standard Deviation 22.83 |
| Alcohol Use Disorder (AUD+) | Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task | 12.77 milliseconds | Standard Deviation 19.78 |
| HCVc | Change in Behavior as Assessed by the Monetary Incentive Delay (MID) Task | 3.63 milliseconds | Standard Deviation 14.17 |
Change in Fatigue Severity Scale (FSS) Score
The Fatigue Severity Scale (FSS) is a 9-item self-report questionnaire designed to measure level of fatigue. The FSS is graded on a 7-point Likert-like scale ranging from 1 (strongly disagree) to 7 (strongly agree). The score for all 9 items is summed to constitute the FSS score. The minimum FSS score is 7 and the maximum score possible is 63. A higher score represents greater fatigue severity. Change was calculated as the value at 6 months minus the value at baseline and reported here. A higher positive score indicates an increase in fatigue symptoms at 6 months compared to baseline, a lower negative score would indicate a decrease in fatigue symptoms over 6 months and a score of 0 would indicate no change in fatigue symptoms over 6 months.
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Change in Fatigue Severity Scale (FSS) Score | 4.87 score on a scale | Standard Deviation 12.95 |
| Alcohol Use Disorder (AUD+) | Change in Fatigue Severity Scale (FSS) Score | 2.46 score on a scale | Standard Deviation 15.05 |
| HCVc | Change in Fatigue Severity Scale (FSS) Score | 4.80 score on a scale | Standard Deviation 11.97 |
Change in Fractional Anisotropy (FA) in White Matter Tracts
MRI-based diffusion tensor imaging (DTI) tractography is used to measure fractional anisotropy (FA), an indicator of CNS microstructural integrity. Increases in FA may reflect enhanced fiber organization or myelination, while decreases often indicate demyelination, axonal loss, or reduced coherence of white matter tracts. The JHU white-matter tractography atlas was used to extract FA values from 20 structures. Percent change was calculated. A positive number indicates an increase in FA after 6 months and a negative number indicates a decrease in FA from baseline to 6 months.
Time frame: Baseline and 6 months
Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, 4 participants (1 Control, 1 AUD, and 2 HCVc) were not included in the analysis because they had missing or corrupted imaging files.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Superior longitudinal fasciculus, temporal part | 0.540 percent change | Standard Deviation 1.543 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Inferior longitudinal fasciculus | 0.474 percent change | Standard Deviation 1.764 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Anterior thalamic radiation | 0.297 percent change | Standard Deviation 2.158 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Superior longitudinal fasciculus, temporal part | -0.017 percent change | Standard Deviation 1.474 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Forceps major | 0.400 percent change | Standard Deviation 2.038 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Cingulum hippocampus | 1.168 percent change | Standard Deviation 3.19 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Uncinate fasciculus | 0.462 percent change | Standard Deviation 3.711 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Corticospinal tract | 0.337 percent change | Standard Deviation 1.045 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Anterior thalamic radiation | 0.416 percent change | Standard Deviation 1.791 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Uncinate fasciculus | -0.409 percent change | Standard Deviation 3.708 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Cingulum hippocampus | -0.113 percent change | Standard Deviation 1.969 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Superior longitudinal fasciculus | 0.424 percent change | Standard Deviation 1.429 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Inferior fronto-occipital fasciculus | 0.014 percent change | Standard Deviation 2.693 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Cingulum cingulate gyrus | 0.340 percent change | Standard Deviation 1.557 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Superior longitudinal fasciculus | -0.284 percent change | Standard Deviation 1.76 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Forceps minor | 0.317 percent change | Standard Deviation 3.4 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Cingulum cingulate gyrus | 0.341 percent change | Standard Deviation 2.384 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Inferior fronto-occipital fasciculus | 0.542 percent change | Standard Deviation 2.558 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Inferior longitudinal fasciculus | 0.017 percent change | Standard Deviation 1.971 |
| Control (AUD-) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Corticospinal tract | 0.130 percent change | Standard Deviation 1.32 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Cingulum cingulate gyrus | -0.095 percent change | Standard Deviation 2.21 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Inferior fronto-occipital fasciculus | 0.005 percent change | Standard Deviation 2.503 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Inferior fronto-occipital fasciculus | -0.410 percent change | Standard Deviation 1.772 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Inferior longitudinal fasciculus | -0.002 percent change | Standard Deviation 1.995 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Superior longitudinal fasciculus | -0.027 percent change | Standard Deviation 1.492 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Superior longitudinal fasciculus | -0.548 percent change | Standard Deviation 1.26 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Inferior longitudinal fasciculus | -0.234 percent change | Standard Deviation 1.834 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Superior longitudinal fasciculus, temporal part | -0.158 percent change | Standard Deviation 1.484 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Superior longitudinal fasciculus, temporal part | -0.671 percent change | Standard Deviation 1.173 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Uncinate fasciculus | 0.341 percent change | Standard Deviation 3.566 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Uncinate fasciculus | -1.324 percent change | Standard Deviation 2.321 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Anterior thalamic radiation | -0.612 percent change | Standard Deviation 2.045 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Cingulum hippocampus | 0.259 percent change | Standard Deviation 2.576 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Anterior thalamic radiation | -0.768 percent change | Standard Deviation 1.85 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Cingulum cingulate gyrus | -0.231 percent change | Standard Deviation 2.41 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Forceps minor | -0.805 percent change | Standard Deviation 2.628 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Cingulum hippocampus | -0.612 percent change | Standard Deviation 2.508 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Corticospinal tract | -0.522 percent change | Standard Deviation 1.402 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Corticospinal tract | -0.166 percent change | Standard Deviation 1.641 |
| Alcohol Use Disorder (AUD+) | Change in Fractional Anisotropy (FA) in White Matter Tracts | Forceps major | -0.295 percent change | Standard Deviation 2.426 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Anterior thalamic radiation | -1.189 percent change | Standard Deviation 1.125 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Superior longitudinal fasciculus | -1.840 percent change | Standard Deviation 0.379 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Forceps major | -2.476 percent change | Standard Deviation 0.821 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Cingulum cingulate gyrus | -2.038 percent change | Standard Deviation 0.731 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Superior longitudinal fasciculus | -1.035 percent change | Standard Deviation 0.744 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Corticospinal tract | -2.396 percent change | Standard Deviation 0.712 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Cingulum cingulate gyrus | -1.218 percent change | Standard Deviation 0.224 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Inferior longitudinal fasciculus | -2.245 percent change | Standard Deviation 1.131 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Inferior fronto-occipital fasciculus | -1.700 percent change | Standard Deviation 0.534 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Cingulum hippocampus | -2.015 percent change | Standard Deviation 3.444 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Inferior longitudinal fasciculus | -1.790 percent change | Standard Deviation 0.358 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Uncinate fasciculus | -1.609 percent change | Standard Deviation 1.299 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Uncinate fasciculus | -1.277 percent change | Standard Deviation 0.614 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Forceps minor | -0.986 percent change | Standard Deviation 1.692 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Superior longitudinal fasciculus, temporal part | -1.525 percent change | Standard Deviation 0.144 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Corticospinal tract | -1.271 percent change | Standard Deviation 0.737 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Cingulum hippocampus | -2.062 percent change | Standard Deviation 0.461 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Anterior thalamic radiation | -1.953 percent change | Standard Deviation 0.888 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Left Superior longitudinal fasciculus, temporal part | -1.363 percent change | Standard Deviation 0.398 |
| HCVc | Change in Fractional Anisotropy (FA) in White Matter Tracts | Right Inferior fronto-occipital fasciculus | -1.756 percent change | Standard Deviation 0.072 |
Change in Mean Diffusivity (MD) in White Matter Tracts
MRI-based diffusion tensor imaging (DTI) tractography is used to measure mean diffusivity (MD), which is the average rate of water diffusion in all directions within brain tissue. An increase in MD often indicates microstructural disruption, such as axonal loss, demyelination, or increased extracellular space due to edema or atrophy and decreases in MD can reflect cellular proliferation or restricted diffusion, as seen in certain types of gliosis or inflammatory conditions. The JHU white-matter tractography atlas was used to extract MD values from 20 structures. Percent change was calculated. A positive number indicates an increase in MD after 6 months and a negative number indicates a decrease in MD from baseline to 6 months.
Time frame: Baseline and 6 months
Population: Only 28 of the 46 participants that completed the study, completed both imaging sessions (baseline and 6 months) and were considered for further imaging analyses. Of the 28 participants, 4 participants (1 Control, 1 AUD, and 2 HCVc) were not included in the analysis because they had missing or corrupted imaging files.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Anterior thalamic radiation | -0.740 percent change | Standard Deviation 1.039 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Anterior thalamic radiation | -0.827 percent change | Standard Deviation 0.993 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Superior longitudinal fasciculus, temporal part | -0.892 percent change | Standard Deviation 1.243 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Corticospinal tract | -0.372 percent change | Standard Deviation 0.985 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Superior longitudinal fasciculus | -0.615 percent change | Standard Deviation 1.116 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Inferior fronto-occipital fasciculus | -1.191 percent change | Standard Deviation 1.161 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Cingulum cingulate gyrus | -0.919 percent change | Standard Deviation 1.566 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Superior longitudinal fasciculus | -0.806 percent change | Standard Deviation 1.237 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Inferior fronto-occipital fasciculus | -0.862 percent change | Standard Deviation 1.155 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Uncinate fasciculus | -0.864 percent change | Standard Deviation 1.716 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Inferior longitudinal fasciculus | -1.006 percent change | Standard Deviation 1.231 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Inferior longitudinal fasciculus | -1.128 percent change | Standard Deviation 1.374 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Corticospinal tract | -0.359 percent change | Standard Deviation 0.701 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Cingulum cingulate gyrus | -0.835 percent change | Standard Deviation 1.458 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Uncinate fasciculus | -1.367 percent change | Standard Deviation 1.541 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Forceps major | -0.474 percent change | Standard Deviation 1.542 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Cingulum hippocampus | -0.797 percent change | Standard Deviation 1.66 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Superior longitudinal fasciculus, temporal part | -0.777 percent change | Standard Deviation 1.093 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Forceps minor | -0.832 percent change | Standard Deviation 1.471 |
| Control (AUD-) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Cingulum hippocampus | -0.932 percent change | Standard Deviation 2.626 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Uncinate fasciculus | 0.582 percent change | Standard Deviation 2.398 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Cingulum cingulate gyrus | -0.177 percent change | Standard Deviation 2.08 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Cingulum hippocampus | 0.099 percent change | Standard Deviation 3.176 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Cingulum hippocampus | 0.015 percent change | Standard Deviation 2.18 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Corticospinal tract | 0.811 percent change | Standard Deviation 1.18 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Corticospinal tract | 0.029 percent change | Standard Deviation 0.928 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Forceps major | 0.756 percent change | Standard Deviation 1.905 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Uncinate fasciculus | -0.334 percent change | Standard Deviation 1.792 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Anterior thalamic radiation | 0.490 percent change | Standard Deviation 1.129 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Forceps minor | 0.302 percent change | Standard Deviation 2.164 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Inferior fronto-occipital fasciculus | -0.014 percent change | Standard Deviation 1.291 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Inferior fronto-occipital fasciculus | 0.276 percent change | Standard Deviation 1.685 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Inferior longitudinal fasciculus | 0.325 percent change | Standard Deviation 1.185 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Inferior longitudinal fasciculus | 0.082 percent change | Standard Deviation 1.67 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Superior longitudinal fasciculus | 0.293 percent change | Standard Deviation 1.154 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Superior longitudinal fasciculus | 0.276 percent change | Standard Deviation 1.532 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Superior longitudinal fasciculus, temporal part | 0.370 percent change | Standard Deviation 1.109 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Superior longitudinal fasciculus, temporal part | 0.284 percent change | Standard Deviation 1.34 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Cingulum cingulate gyrus | 0.453 percent change | Standard Deviation 1.269 |
| Alcohol Use Disorder (AUD+) | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Anterior thalamic radiation | 0.358 percent change | Standard Deviation 1.662 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Forceps minor | -0.674 percent change | Standard Deviation 1.426 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Cingulum cingulate gyrus | 0.521 percent change | Standard Deviation 0.847 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Superior longitudinal fasciculus | 0.724 percent change | Standard Deviation 1.051 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Anterior thalamic radiation | 0.159 percent change | Standard Deviation 1.507 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Anterior thalamic radiation | 0.393 percent change | Standard Deviation 1.856 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Superior longitudinal fasciculus, temporal part | 0.516 percent change | Standard Deviation 0.272 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Forceps major | 1.771 percent change | Standard Deviation 0.407 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Cingulum hippocampus | 2.535 percent change | Standard Deviation 1.258 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Superior longitudinal fasciculus, temporal part | 0.282 percent change | Standard Deviation 0.952 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Corticospinal tract | 1.169 percent change | Standard Deviation 1.674 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Uncinate fasciculus | -0.633 percent change | Standard Deviation 0.121 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Corticospinal tract | 0.522 percent change | Standard Deviation 0.881 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Cingulum cingulate gyrus | -0.288 percent change | Standard Deviation 1.983 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Inferior longitudinal fasciculus | 1.089 percent change | Standard Deviation 0.099 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Inferior fronto-occipital fasciculus | 0.861 percent change | Standard Deviation 1.655 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Uncinate fasciculus | 0.586 percent change | Standard Deviation 1.752 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Inferior longitudinal fasciculus | 1.095 percent change | Standard Deviation 0.914 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Inferior fronto-occipital fasciculus | 0.240 percent change | Standard Deviation 0.238 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Right Cingulum hippocampus | 1.131 percent change | Standard Deviation 4.55 |
| HCVc | Change in Mean Diffusivity (MD) in White Matter Tracts | Left Superior longitudinal fasciculus | 0.249 percent change | Standard Deviation 0.342 |
Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB)
This outcome measure evaluates the change in the number of days of alcohol use from baseline to a 6-month follow-up, using the 30-Day Timeline Followback (TLFB) method. The TLFB is a structured, retrospective interview technique that allows participants to accurately recall their alcohol consumption patterns over the previous 30 days. For this outcome, the number of days on which alcohol was consumed will be assessed at baseline (the start of the study) and again at the 6-month follow-up assessment. A positive change would indicate an increase in the number of days of alcohol use, while a negative change would indicate a reduction in the number of days of alcohol use over the 6-month period.
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB) | 3.78 change in the number of days of alcohol | Standard Deviation 9.69 |
| Alcohol Use Disorder (AUD+) | Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB) | 44.00 change in the number of days of alcohol | Standard Deviation 81.85 |
| HCVc | Changes in Alcohol Use Measured Using the Timeline Follow Back (TLFB) | -6.25 change in the number of days of alcohol | Standard Deviation 12.5 |
Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR)
Change was calculated as the value at 6 months minus the value and baseline. A positive number indicates an increase in inflammatory markers in plasma samples and a negative value indicates a decrease in inflammatory markers at 6 months.
Time frame: Baseline and 6 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Control (AUD-) | Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | NLR | -0.36 cell count x 10^3/uL [ratio] | Standard Deviation 0.58 |
| Control (AUD-) | Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | MLR | -0.03 cell count x 10^3/uL [ratio] | Standard Deviation 0.07 |
| Alcohol Use Disorder (AUD+) | Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | NLR | 0.17 cell count x 10^3/uL [ratio] | Standard Deviation 0.52 |
| Alcohol Use Disorder (AUD+) | Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | MLR | 0.03 cell count x 10^3/uL [ratio] | Standard Deviation 0.07 |
| HCVc | Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | NLR | -0.50 cell count x 10^3/uL [ratio] | Standard Deviation 0.42 |
| HCVc | Changes in Inflammatory Profile Markers: Neutrophil to Lymphocyte Ratio (NLR) and Monocyte to Lymphocyte Ratio (MLR) | MLR | 0.45 cell count x 10^3/uL [ratio] | Standard Deviation 0.7 |
Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores
The Attention Module is a marker of attentional capacity, working memory, and processing speed. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Attention Module subtests include: Dots, Numbers and Letters, Driving Scenes, Digits Forward, and Digits Backward. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in attention performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of attention performance over time.
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores | 10.99 Units on a scale | Standard Deviation 3.37 |
| Alcohol Use Disorder (AUD+) | Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores | 0.31 Units on a scale | Standard Deviation 1.18 |
| HCVc | Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores | 6.35 Units on a scale | Standard Deviation 5.92 |
Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores
The Executive Functions Module of the NAB is a marker of executive function, including problem-solving and mental flexibility. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Executive Function Module subtests include: Mazes, Judgement, Categories, and Word Generation. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in executive function performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of executive functioning performance over time.
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores | 10.65 Units on a scale | Standard Deviation 0.25 |
| Alcohol Use Disorder (AUD+) | Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores | 5.46 Units on a scale | Standard Deviation 1.01 |
| HCVc | Changes in Neuropsychological Assessment Battery (NAB) Executive Functions Module Scores | 18.00 Units on a scale | Standard Deviation 14.14 |
Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores
The Memory Module is a marker of learning, recall, and recognition memory. T-scores are derived by converting raw scores using normative tables that account for age and education. T-scores range from 20 to 80 with a mean of 50 and standard deviation of 10. Lower T-scores (below 40) indicate below average performance and higher T-scores (above 60) indicate above-average performance. NAB Memory Module subtests include: List Learning, Shape Learning, Story Learning, and Daily Living Memory. Subtest scores were averaged to compute a total score. Change was calculated as the value at 6 months minus the value at baseline. Larger numbers represent greater improvement in memory performance, a score of 0 indicates no change in performance and negative numbers indicate a worsening of memory performance over time.
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Control (AUD-) | Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores | 9.07 Units on a scale | Standard Deviation 1.12 |
| Alcohol Use Disorder (AUD+) | Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores | 1.95 Units on a scale | Standard Deviation 1.52 |
| HCVc | Changes in Neuropsychological Assessment Battery (NAB) Memory Module Scores | 3.50 Units on a scale | Standard Deviation 0.71 |